Showing 1,526 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Access to healthcare

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

News
10 April 2025
Pharmaceutical industry

Johnson & Johnson Unit Ordered to Pay $1.64 Billion in HIV Drug Marketing Case

Editor's pick
Medscape (requires free registration)
1 April 2025
Pharmaceutical industry

Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts

Editor's pick
FiercePharma
27 March 2025
Pharmaceutical industry

After Gilead and J&J lawsuits, distributor Safe Chain sees its owners charged in criminal indictment

Editor's pick
FiercePharma
5 July 2024
Access to healthcare

‘Inward, Technocratic’ MSF Leadership Under Global Pressure to Reverse Decision to Close Access Campaign

Editor's pick
Health Policy Watch
26 June 2024
Injectable & long-acting PrEP

No HIV infections seen in groundbreaking trial of twice-yearly injectable PrEP

News
22 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Access to healthcare

Children in Kenya and Uganda experiencing stock-outs of crucial HIV medicines like dolutegravir

News
14 June 2024
Pharmaceutical industry

HIV drugmaker Gilead Sciences agrees to $40m settlement over claims it delayed treatment rollout

Editor's pick
Irish Independent
10 June 2024
HIV treatment for children & young people

Johnson & Johnson Submits Supplemental New Drug Application to Expand Indication of Prezcobix for HIV-1 in Children at Least 6 Years Old

Editor's pick
Pharmaceutical Executive
7 June 2024
Access to healthcare

Celebrities join campaigners in call for cheaper version of ‘gamechanger’ HIV drug for poorer countries

Editor's pick
The Guardian
30 May 2024
Pharmaceutical industry

Blockbuster Drug Patent Thickets Signal 'Strategic Behavior'

Editor's pick
MedPage Today
14 May 2024
Pharmaceutical industry

Opinion: Creating the next wave of antibody therapies requires innovative collaboration

Editor's pick
STAT
6 May 2024
Access to healthcare

Colombia Issues Compulsory License to Get Key Generic HIV Medicine, Dolutegravir

Editor's pick
Health Policy Watch
26 April 2024
Access to healthcare

ViiV Healthcare statement on compulsory licence for dolutegravir in Colombia

Editor's pick
ViiV press release
25 April 2024
Pharmaceutical industry

British Columbia class action suit approved against HIV/AIDS drugmaker Gilead

Editor's pick
Vancouver Sun
26 March 2024
New & experimental HIV treatments

CytoDyn finally clears FDA hold on HIV program after 2 years

Editor's pick
FierceBiotech
8 March 2024
Access to healthcare

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

Editor's pick
Médecins Sans Frontières
9 February 2024
New & experimental HIV treatments

CytoDyn announces submission of revised HIV clinical trial protocol to FDA

Editor's pick
CytoDyn press release
6 February 2024
Pharmaceutical industry

Appeals court allows unique argument in Gilead's legal battle over HIV meds

Editor's pick
FiercePharma
15 January 2024
New & experimental HIV treatments

Calibr announces license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir

Editor's pick
EurekAlert!
8 January 2024